Originally published as JCO Early Release 10.1200/JCO.2005.01.515 on July 11 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Faynsod, M. Articles by Leong, L. A. Search for Related Content PubMed PubMed Citation Articles by Faynsod, M. Articles by Leong, L. A. Related Articles Related Editorial Social Bookmarking                            What's this?

Improved Hepatic Toxicity Profile of Portal Vein Adjuvant Hepatic Infusional Chemotherapy

From the Divisions of Surgery, Medical Oncology, and Bioinformatics, City of Hope National Medical Center, Duarte, CA

Address reprint requests to Lawrence D. Wagman, MD, FACS, City of Hope National Medical Center, Division of Surgery, 1500 E Duarte Rd, Duarte, CA 91010-3000; e-mail: lwagman{at}coh.org

PURPOSE: To determine whether floxuridine (FUDR) can be delivered with low hepatic toxicity through the portal vein (PV) as an adjuvant to surgically treated colorectal metastases.

PATIENTS AND METHODS: Fifty-one patients undergoing complete resection and/or ablation for colorectal hepatic metastases were prospectively enrolled at a National Cancer Institute–designated comprehensive cancer center. Two sequential phase II trials were performed. Each trial included complete surgical treatment followed by sequential, alternating (22 patients) or concurrent (29 patients) regional PV FUDR and systemic fluorouracil (FU) with leucovorin chemotherapy.

RESULTS: Fifty percent of patients were male. The mean age at diagnosis was 57 years. The mean number of lesions resected was three (range, one to 11 lesions). The stage at diagnosis was II, III, and IV in 16.9%, 52.8%, and 28.3% of patients, respectively. One- and 3-year overall survival rates were 92.7% and 41.8%, respectively. The 1- and 3-year disease-free survival rates were 64.5% and 19%, respectively. The site of first recurrence was hepatic in 35.9% of patients. Treatment was terminated early in 24 patients (17 patients progressed, two refused treatment, and five had nonhepatic toxicities). Fifty-five percent of patients received 75% to 100% of the planned FUDR courses, and 72% received greater than 50% of the planned FUDR dose. Only four patients required dose reductions of FUDR because of grade 3 hepatic toxicity. No patient required biliary stenting or had discontinuation of PV infusion because of hepatic toxicity.

CONCLUSION: The delivery of PV FUDR and FU with leucovorin can be performed with a high percentage of expected drug delivery and a low drug-induced hepatic toxicity rate, while achieving acceptable overall and disease-free survival.

Supported by grant No. CA 33572.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• A Role for Hepatic-Directed Chemotherapy in Colorectal Liver Metastases
  William D. Ensminger
  JCO 2005 23: 4815-4817 [Full Text]

This article has been cited by other articles:

				W. D. Ensminger A Role for Hepatic-Directed Chemotherapy in Colorectal Liver Metastases J. Clin. Oncol., August 1, 2005; 23(22): 4815 - 4817. [Full Text] [PDF]